Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ArQule, Daiichi Sankyo sign SPA agreement with FDA
Daiichi Sankyo, the holder of the investigational new drug application for ARQ 197 and ArQule’s partner for the development of the compound, will conduct the Phase 3 trial,
Daiichi Sankyo, the holder of the investigational new drug application for ARQ 197 and ArQule’s partner for the development of the compound, will conduct the Phase 3 trial,
The pre-clinical research was presented at the 8th International M Judah Folkman Conference in Cambridge, Massachusetts, highlighting significant advances in the systemic delivery of RNAi therapeutics. In the
The active ingredient in NeuroSTAT, cyclosporin-A, has been used for immunosuppression such as in organ transplantation, NeuroVive said. NeuroVive Pharma CEO Mikael Bronnegard said that the orphan drug
In the study, BSI-201demonstrated that treatment with the drug in combination with gemcitabine/carboplatin results in a improvement in overall survival and a high rate of clinical response in
Prior to joining PepTcell, Scheske served as president of Consumer Healthcare Europe at GlaxoSmithKline (GSK) for over 25 years. Scheske, who was president of GSK’s European Consumer Healthcare
FDA said that Sibutramine is not listed on the product label and could harm consumers, especially those with cardiovascular conditions. FDA lab tests revealed that the product contains
Bexion Pharma has received the Phase II SBIR grant to identify and select optimised SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion’s drug toward
OpRegen is a proprietary formulation of embryonic stem cell-derived retinal pigment epithelial cells designed by Cell Cure to help save the sight of the baby boomer generation. The
In September 2008, Merck Serono and Ablynx entered into an agreement to co-discover and co-develop nanobodies against two targets in oncology and immunology. Merck Serono and Ablynx’s new
Results from the LUX-Lung 1 trial suggest that Afatinib is highly active in late-stage patients with NSCLC1, while in the LUX-Lung 2 Phase II trial Afatinib demonstrated encouraging